Tecentriq 1 875 mg solution for injection
*Company:
Roche Registration GmbHStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 22 October 2024
File name
TCN_SmPC_SC_II88_19Sep2024.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 22 October 2024
File name
TCN_PIL_SC_II88_19Sep2024.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 29 August 2024
File name
SmPC_Tecentriq 1875 mg_II-0082_26Aug2024.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 24 June 2024
File name
TCN_IAin_SC_PIL_dated 20Jun2024.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 24 June 2024
File name
TCN_IAin_SC_SmPC_dated 20Jun2024.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 28 May 2024
File name
TEC_SC_II84_PIL_11Apr2024.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Change to information for healthcare professionals
Updated on 28 May 2024
File name
TEC_SC_II84_SmPC_11Apr2024.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 22 March 2024
File name
TCN-SmPC-1875mg-220224.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
File name
Tecentriq Patient Card IE Version 26.1.3 (1).pdf
Reasons for updating
- Add New Doc
Updated on 29 February 2024
File name
TCN-PIL-1875mg-22feb2024.pdf
Reasons for updating
- Change to improve clarity and readability
Updated on 29 February 2024
File name
TCN-SmPC-1875mg-22feb2024.pdf
Reasons for updating
- Document format updated
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 27 February 2024
File name
TCN-1875mg PIL 22Feb24.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
Updated on 27 February 2024
File name
TCN-1875mg SmPC 22Feb24.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 January 2024
File name
IRL-TCN-1875mg-SmPC.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 January 2024
File name
IRL-TCN-1875mg_PIL.pdf
Reasons for updating
- New PIL for new product